Biohaven’s oral migraine drug performed well in a pivotal clinical trial in China and South Korea, the company reports.
Rimegepant, the New Haven biotech’s calcitonin gene-related peptide receptor antagonist, showed positive top-line results in a Phase 3 clinical trial involving 1,431 adults in the two countries.